Jun 2, 2025 · During the weight-loss phase, patients were randomized to receive semaglutide alone or in combination with two different doses of trevogrumab (lower- or higher-dose …

Jun 4, 2025 · Recent clinical research has explored the combination of semaglutide (a GLP-1 receptor agonist), trevogrumab (a myostatin inhibitor), and garetosmab (an activin A inhibitor) …

Jun 14, 2024 · Trevogrumab (a monoclonal antibody [mAb]) binds and blocks myostatin signalling, while garetosmab (a mAb) binds and blocks activin A, AB and AC signalling. Here, …

Mar 7, 2024 · This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study …

Jun 3, 2025 · The greatest improvements were seen in the triplet therapy arm, which combined semaglutide, trevogrumab, and garetosmab. This group exhibited the highest lean mass …

Jun 10, 2025 · In the ongoing phase 2 COURAGE clinical trial, novel combinations of semaglutide (Ozempic, Rybelsus, Wegovy; Novo Nordisk), a glucagon-like peptide-1 receptor agonist (GLP …

Jun 2, 2025 · Results from a phase 2 trial showed that semaglutide combined with trevogrumab, with or without garetosmab, helped patients preserve lean mass and achieve greater fat loss.

Jun 2, 2025 · The study is investigating novel combinations of trevogrumab with or without a second antibody garetosmab (anti-activin A) added to semaglutide, according to a Regeneron …

Feb 28, 2024 · The purpose of this study is to assess the effect of the addition of trevogrumab or trevogrumab with garetosmab to semaglutide on body weight and fat mass, versus …

Jun 2, 2025 · However, a triple combination of Novo's semaglutide, Regeneron's trevogrumab and experimental antibody garetosmab led to a substantially higher rate of discontinuation due …